Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor Regulatory T cell infusion with sirolimus in steroid-refractory chronic graft-versus-host disease
2012-000301-71Phase 2Terminated
- Sponsor
- Centre Hospitalier Universitaire de Liège
- Start
- Dec 2012
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous regulatory T-lymphocytes in graft-versus-host disease (GVHD) and chronic graft-versus-host disease (cGVHD), sponsored by Centre Hospitalier Universitaire de Liège. Started Dec 2012; status: terminated.
02
Drugs
autologous regulatory T-lymphocytes
03
Conditions
graft-versus-host disease (GVHD)chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2012-000301-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000301-71.